HLA and risk of diffuse large B-cell lymphoma after solid organ transplantation

Details

• Alternative Title:
  Transplantation
• Personal Author:
  Hussain, Shehnaz K. ; Makgoeng, Solomon B. ; Everly, Matthew J. ; Goodman, Marc T. ; Martínez-Maza, Otoniel ; Morton, Lindsay M. ; Clarke, Christina A. ; Lynch, Charles F. ; Snyder, Jon ; Israni, Ajay ; Kasiske, Bertram L. ; Engels, Eric A.
• Description:
  Background
  
  Solid organ transplant recipients have heightened risk for diffuse large B-cell lymphoma (DLBCL). The role of donor-recipient HLA mismatch and recipient HLA type on DLBCL risk are not well established.
  
  Methods
  
  We examined 172,231 U.S. kidney, heart, pancreas, and lung recipients transplanted between 1987 and 2010, including 902 with DLBCL. Incidence rate ratios (IRRs) were calculated using Poisson regression for DLBCL risk in relation to HLA mismatch, types, and zygosity, adjusting for sex, age, race/ethnicity, year, organ, and transplant number.
  
  Results
  
  Compared to recipients who had two HLA-DR mismatches, those with zero or one mismatches had reduced DLBCL risk, (zero: IRR=0.76, 95%CI=0.61–0.95; one: IRR=0.83, 95%CI=0.69–1.00). In stratified analyses, recipients matched at either HLA-A, -B, or -DR had a significantly reduced risk of late-onset (>2 years after transplantation), but not early-onset, DLBCL, and there was a trend for decreasing risk with decreasing mismatch across all three loci (P=0.0003). Several individual recipient HLA-A, -B, -C, -DR, and –DQ antigens were also associated with DLBCL risk, including DR13 (IRR=0.74, 95%CI=0.57–0.93) and B38 (IRR=1.48, 95%CI=1.10–1.93), confirming prior findings that these two antigens are associated with risk of infection-associated cancers.
  
  Conclusions
  
  In conclusion, variation in HLA is related to susceptibility to DLBCL, perhaps reflecting intensity of immunosuppression, control of Epstein-Barr virus infection among transplant recipients, or chronic immune stimulation.
  
  
• Subjects:
  Adult Female Histocompatibility Testing HLA-DR Antigens HLA Antigens Humans Lymphoma, Large B-Cell, Diffuse Male Middle Aged Organ Transplantation Risk

  More +
• Source:
  Transplantation. 100(11):2453-2460.
• Pubmed ID:
  26636741
• Pubmed Central ID:
  PMC4893345
• Document Type:
  Journal Article
• Funding:
  U58 DP003931/DP/NCCDPHP CDC HHS/United States ; K07 CA140360/CA/NCI NIH HHS/United States ; HHSN261201000037C/CA/NCI NIH HHS/United States ; N01PC35143/CA/NCI NIH HHS/United States ; HHSN261201000035C/PC,CA/None/None ; U58 DP003883/DP/NCCDPHP CDC HHS/United States ; U58 DP003875/DP/NCCDPHP CDC HHS/United States ; P30 CA086862/CA/NCI NIH HHS/United States ; HHSN261201000036C/CA/NCI NIH HHS/United States ; U58 DP003879/DP/NCCDPHP CDC HHS/United States ; N01PC35137/CA/NCI NIH HHS/United States ; HHSN261201300071C/CA/NCI NIH HHS/United States ; U58 DP003920/DP/NCCDPHP CDC HHS/United States ; HHSN261201300011C/RC/CCR NIH HHS/United States ; U58 DP000807/DP/NCCDPHP CDC HHS/United States ; N01PC35142/CA/NCI NIH HHS/United States ; HHSN261201300021C/CA/NCI NIH HHS/United States ; HHSN261201000035I/CA/NCI NIH HHS/United States ; U58 DP000848/DP/NCCDPHP CDC HHS/United States ; HHSN261201000024C/CA/NCI NIH HHS/United States ; HHSN261201000034C/CA/NCI NIH HHS/United States ; U58 DP003921/DP/NCCDPHP CDC HHS/United States ; HHSN261201300011I/CA/NCI NIH HHS/United States ; U58 DP000832/DP/NCCDPHP CDC HHS/United States ; N01PC35139/CA/NCI NIH HHS/United States ; U58 DP000824/DP/NCCDPHP CDC HHS/United States
• Volume:
  100
• Issue:
  11
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:baf6368878684dd1d2df94ab403fa5d66597e26094b2bd7097b095849e4ee526
• Download URL:
  https://stacks.cdc.gov/view/cdc/42119/cdc_42119_DS1.pdf
• File Type:
  [PDF - 116.45 KB ]